EQS-News: Liberation from renal replacement therapy and early initiation to be supported by the kidney function biomarker Proenkephalin A 119-159 (penKid)
PenKid identified as a promising kidney function biomarker to support future precision medicine approaches for RRT-dependent AKI.
- PenKid identified as a promising kidney function biomarker to support future precision medicine approaches for RRT-dependent AKI.
- Hennigsdorf, Germany, December 15, 2022 - The diagnostic company SphingoTec GmbH (SphingoTec) announces first data on the kidney function biomarker penKid as a promising tool in supporting early initiation and liberation from RRT (1).
- Proenkephalin A 119–159 predicts early and successful liberation from renal replacement therapy in critically ill patients with acute kidney injury: a post hoc analysis of the ELAIN trial.
- Scientific evidence shows that penKid also reflects kidney function in children, representing a potential biomarker for pediatric AKI.